Skip to main content
SpringerLink
Log in

Pegvisomant prevents diabetes in acromegaly, saves costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was sponsored by Pfizer (Spain).

Reference

  • Sanchez-Cenizo L, et al. Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain. ClinicoEconomics and Outcomes Research : 22 Jul 2019. Available from: URL: https://doi.org/10.2147/CEOR.S204276

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pegvisomant prevents diabetes in acromegaly, saves costs. PharmacoEcon Outcomes News 834, 29 (2019). https://doi.org/10.1007/s40274-019-6129-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6129-6

Search

Navigation